Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Doug Kohrs
AddedMar 31, 2024
UpdatedMay 31, 2026
Doug Kohrs

Doug Kohrs

Board Member, Disc Dynamics

Crunchbase

Doug Kohrs's Career

Disc Dynamics
Disc Dynamics

Eden Prairie, MN, US

Board Member· Board
Vergent Bioscience
Vergent Bioscience

Minneapolis, MN, US

Board Member· Board
Omniguide
Omniguide

Lexington, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Doug Kohrs's Career

Disc Dynamics
Disc Dynamics
Series F$59.6M302000Eden Prairie, MN, US
Board Member· Board

Leadership at Disc Dynamics

Jeffrey Felt, M.D.Jeffrey Felt, M.D.Founder
Dave StassenDave StassenBoard Member
Dr Hansen A YuanDr Hansen A YuanBoard Member

Similar to Disc Dynamics

DiscGenicsDiscGenicsSalt Lake City, UT, USRegenerative Therapiesest. 2007DiscGenicsSalt Lake City, UT, US · est. 2007

DiscGenics: Developing regenerative therapies for spinal degenerative diseases to alleviate pain.

Series C · $68M52
Baxano SurgicalBaxano SurgicalRaleigh, NC, USMedical Devicesest. 2000Baxano SurgicalRaleigh, NC, US · est. 2000

Baxano Surgical, Inc.: Innovating spinal solutions for degenerative disc disease.

Public · $25M75
DymicronDymicronOrem, UT, USMedical Devicesest. 2009DymicronOrem, UT, US · est. 2009

Dymicron, Inc.: Innovating musculoskeletal implant devices using exclusive, patented polycrystalline diamond technology.

Series A · $4.1M35
Elevate DynamicsElevate DynamicsSan Diego, CA, USHealthcare Productsest. 2019Elevate DynamicsSan Diego, CA, US · est. 2019

Elevate Dynamics: Innovatively designed healthcare products for enhanced mobility and pain relief.

Seed · $8.8M30
Vergent Bioscience
Vergent Bioscience
Series B$34.4M132016Minneapolis, MN, US
Board Member· Board

Leadership at Vergent Bioscience

Dean BanksDean BanksBoard Member
Dean B.Dean B.Board Member
Jeff JulkowskiJeff JulkowskiCo-Founder
John SantiniJohn SantiniCEO

Similar to Vergent Bioscience

CytoVerisCytoVerisFarmington, CT, USImaging Solutionsest. 2018CytoVerisFarmington, CT, US · est. 2018

AI-driven imaging solutions by CytoVeris, enhancing cancer detection and patient outcomes.

Series B · $8M23
Blaze BioscienceBlaze BioscienceSeattle, WA, USImaging, Tumor Paintest. 2010Blaze BioscienceSeattle, WA, US · est. 2010

Seattle-based Blaze Bioscience develops tumor paint technology for precise, real-time cancer cell visualization.

Series B · $55.4M38
On Target LaboratoriesOn Target LaboratoriesNorthbrook, IL, USCancer Detectionest. 2010On Target LaboratoriesNorthbrook, IL, US · est. 2010

On Target Laboratories innovates in developing and commercializing cell-targeting molecules for various cancers.

Series C · $111.7M75
Surge TherapeuticsSurge TherapeuticsCambridge, MA, USCancer Treatmentest. 2016Surge TherapeuticsCambridge, MA, US · est. 2016

SURGE: Innovating cancer treatment through targeted, timely immunotherapy for improved survival.

Series B · $58M7
Omniguide
Omniguide
Series F$129.8M3752000Lexington, MA, US
Board Member· Board

Leadership at Omniguide

Matt JenningsMatt JenningsBoard Member
Nicholas KonidarisNicholas KonidarisBoard Member
Yoel FinkYoel FinkBoard Member
Vickie CappsVickie CappsBoard Member
Lisa SuennenLisa SuennenBoard Member
Ray StataRay StataBoard Member

Similar to Omniguide

OmnioxOmnioxSan Carlos, CA, USBiotechest. 2006OmnioxSan Carlos, CA, US · est. 2006

US-based Omniox, a biotech firm, innovates in cancer, cardiovascular disease, and trauma treatment.

Series D · $20.1M7
Cambridge Endoscopic DevicesCambridge Endoscopic DevicesFramingham, MA, USMedical Devicesest. 2004Cambridge Endoscopic DevicesFramingham, MA, US · est. 2004

Cambridge Endoscopic Devices: Innovating hand-held laparoscopic instruments for enhanced medical procedures.

Seed · $9.1M30
Clear Guide MedicalClear Guide MedicalBaltimore, MD, USMedical Devicesest. 2010Clear Guide MedicalBaltimore, MD, US · est. 2010

US-based Clear Guide Medical, LLC manufactures electromedical and electrotherapeutic apparatus in Baltimore.

Seed · $8.8M13
ResoneticsResoneticsNashua, NH, USMicro Manufacturingest. 1987ResoneticsNashua, NH, US · est. 1987

Leading technical innovator in micro manufacturing for life sciences, specializing in laser operations.

Private Equity · $1.1B30

Doug Kohrs's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Doug Kohrs

Jim FitzsimmonsJim FitzsimmonsBoard Member · Cardiac DimensionsDavid WellsDavid WellsBoard Member · Ionic MaterialsTed DriscollTed DriscollBoard Member · NuMediiJohn PavlidisJohn PavlidisBoard Member · VytronUSRay KraussRay KraussCEO · Agile EndoSurgery